will tirzepatide go back on the shortage list https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Lilly (LLY) CEO Says Weight-Loss

(PubMed) Wolffenbuttel BH, Owen PJ, Ward M, Green R

10.2 Thyroid C-cell Tumor Risk (Animal Studies Context) Early data point to a possible risk

Consider this scenario: a patient in the Bay Area has a BMI of 32 and has tried semaglutide-based treatment without reaching her weight loss goals

This is particularly concerning given that people with obesity-related comorbidities may reap the greatest benefit from treatment. Thomsen noted the irony that patients most likely to benefit from sustained treatment were often those most likely to abandon it due to side effects or other health complications

Then theres the big oneexercise

When will I see the results of Medical Weight Loss